Epidemiology, Clinical Characteristics and Treatment Outcomes of Acinetobacter baumannii Infection at a Regional Hospital in Thailand by Sakulkonkij P, Bruminhent J

“…Additionally, multivariate analysis showed that predictors of unfavorable outcomes, such as multiorgan failure, hypoalbuminemia, hematologic malignancy, and healthcare-associated pneumonia. …”
Get full text

Cellular heterogeneity and cytokine signatures in acute myeloid leukemia: A novel prognostic model by Jinxia Cao, Bin Hu, Tianqi Li, Dan Fang, ling Jiang, Jun Wang

“…Acute Myeloid Leukemia (AML) is a complex hematological malignancy distinguished by its heterogeneity in genetic aberrations, cellular composition, and clinical outcomes. …”
Get full text

Pulmonary aspergillosis in US Veterans with COVID-19: a nationwide, retrospective cohort study by Kaitlin Swinnerton, Nathanael R. Fillmore, Ikwo Oboho, Janet Grubber, Mary Brophy, Nhan V Do, Paul A Monach, Westyn Branch-Elliman

“…Selected clinical characteristics included age >70, receipt of immune-compromising drugs, hematologic malignancy, chronic respiratory disease, vaccination status, and vaccine era. …”
Get full text

HDAC10 and its implications in Sézary syndrome pathogenesis by Monika Pieniawska, Karolina Rassek, Bogumiła Skwara, Magdalena Żurawek, Iwona Ziółkowska-Suchanek, Lydia Visser, Monique Lodewijk, Małgorzata Sokołowska-Wojdyło, Małgorzata Sokołowska-Wojdyło, Berenika Olszewska, Roman J. Nowicki, Roman J. Nowicki, Tomasz Stein, Aleksandra Dańczak-Pazdrowska, Adriana Polańska, Marta Szymoniak-Lipska, Natalia Rozwadowska, Katarzyna Iżykowska

“…Cutaneous T-cell lymphomas (CTCL) are a group of rare hematological malignancies characterized by infiltration of malignant T-cells into the skin. …”
Get full text

BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia by Xu Sang, Yongping Zhang, Fang Fang, Li Gao, Yanfang Tao, Xiaolu Li, Zimu Zhang, Jianwei Wang, Yuanyuan Tian, Zhiheng Li, Di Yao, Yumeng Wu, Xinran Chu, Kunlong Zhang, Li Ma, Lihui Lu, Yanling Chen, Juanjuan Yu, Ran Zhuo, Shuiyan Wu, Zhen Zhang, Jian Pan, Shaoyan Hu

“…AML (acute myeloid leukemia) is a common hematological malignancy in children with poor treatment effects and poor prognosis. …”
Get full text

A Retrospective Observational Cohort Analysis of Oncology Patients with Febrile Neutropenia in the Emergency Department of a Tertiary Care Hospital in Oman by Badar Al-Aamri, Aisha AL Breiki, Darpanarayan Hazra, Talib Al-Aamri, Manar Al-Shehi

“…Of these, 52.9% were classified as low risk, with 44.6% having hematological malignancies and 55.4% having solid malignancies. …”
Get full text

Intestinal obstruction caused by disseminated mycobacterium avium complex disease following solid organ transplantation: a case report by Akane Mita, Sho Nakakubo, Yusuke Nishimura, Hideki Shima, Masaaki Watanabe, Tsuyoshi Shimamura, Satoshi Konno

“…Disseminated MAC disease occurs mainly in immunocompromised individuals, such as those with acquired immunodeficiency syndrome, hematological malignancies, or those positive for anti-interferon-γ antibodies. …”
Get full text

Long-term trends in the burden of multiple myeloma in China: a Joinpoint regression and age-period-cohort analysis based on GBD 2021 by Yanyu Zhang, Quanxin Su, Jiawen Yu, Xiuli Sun

“…PurposeMultiple myeloma (MM) is a hematologic malignancy originating from plasma cells with clinical manifestations such as hypercalcemia, cytopenias (most commonly anemia) and renal failure. …”
Get full text

Integrating rapamycin with novel PI3K/Akt/mTOR inhibitor microRNAs on NOTCH1-driven T-cell acute lymphoblastic leukemia (T-ALL) by Fateme Arjmand, Samaneh Shojaei, Mitra Khalili, Hossein Dinmohammadi, Behzad Poopak, Samira Mohammadi-Yeganeh, Yousef Mortazavi

“…Rapamycin is a potential therapeutic strategy for hematological malignancies due to its ability to suppress mTOR activity. …”
Get full text

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors by Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna

“…Rationale of the trial Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. …”
Get full text